The state of play in overcoming resistance to RAF inhibition in metastatic melanoma - where do we go next?
Is CDK12 deficiency a clinically relevant predictive biomarker of PARP1/2 inhibitor sensitivity?
CAR T cells and PD-1 antibodies are two of the hottest topics in immunotherapy right now, but what would happen if you combined them?